GLP-1 and tirzepatide: what makes this medicine different

What does it actually mean that tirzepatide is a GLP-1 and GIP receptor agonist?

Most people have heard the term GLP-1 used as shorthand for this entire class of medicines, but tirzepatide sits in a slightly different category. GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating; it signals fullness to the brain, slows the rate at which food leaves the stomach, and nudges insulin secretion in response to glucose. Medicines that mimic it have existed for over a decade, mainly in diabetes care.

Tirzepatide adds a second signal: GIP, or glucose-dependent insulinotropic polypeptide. GIP is released earlier in the digestive process and works alongside GLP-1 to regulate appetite and energy storage. The two receptors appear to reinforce each other, activating both together produces a stronger appetite-suppressing effect than either signal alone. That is the core reason tirzepatide produced greater average weight loss than semaglutide 2.4 mg in the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025. If you want to explore how the two medicines compare side by side, our tirzepatide and Mounjaro comparison page covers that evidence in more detail.

None of this means tirzepatide is right for everyone. The dual-pathway effect also explains some of the side effects, since slowing gastric emptying is exactly what causes the nausea and digestive discomfort many people notice early in treatment.

Who does the UK licence actually cover, and what does eligibility look like in practice?

The UK licence for tirzepatide (sold as Mounjaro) covers adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition, for example, high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI figure alone does not determine whether tirzepatide is prescribed; a prescriber reviews your full health picture, your current medicines and your history before making a clinical decision.

NICE recommended tirzepatide in December 2024 (appraisal TA1026) for NHS use, but access through the health service is rolling out in phases with strict criteria and waiting periods. For people who do not meet the current NHS thresholds or who prefer not to wait, a regulated private pharmacy is the legal alternative, again, only via a valid prescription following clinical assessment. Our tirzepatide overview page outlines how the private route works step by step.

For those interested in what the full tirzepatide licence covers, including the diabetes indication, this page on tirzepatide's GLP-1 classification addresses common questions about how the two licences relate.

What do side effects look like, and when do they tend to ease?

The most commonly reported side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, reflux and burping. Headache, fatigue and dizziness appear less often. These effects tend to be most noticeable in the first days after starting treatment or after a dose increase, and for many people they settle within roughly one to two weeks as the body adjusts. Starting at 2.5 mg (the opening dose in the schedule) exists specifically to give the system time to adapt before any increase is considered.

There are rarer but more serious signs to know. Severe, persistent stomach pain that radiates towards the back can indicate acute pancreatitis, which is a known though infrequent risk with GLP-1 medicines; the MHRA highlighted this in a Drug Safety Update in January 2026 and advises seeking urgent medical help if that symptom pattern develops. Signs of a gallbladder problem, any allergic reaction, or sudden changes to vision should also prompt an immediate call to a healthcare professional. Patients can report suspected side effects directly to the MHRA via the Yellow Card scheme.

Women taking oral contraceptives should discuss their method with a prescriber when starting tirzepatide, since reduced pill absorption during the early weeks of treatment and after each dose step means a non-oral method may be advised alongside it. Your Patient Information Leaflet and prescriber are the definitive guide here, individual circumstances vary.

How is tirzepatide taken, and what does the routine actually look like?

Tirzepatide comes as a once-weekly injection delivered via a pre-filled KwikPen. Each pen contains four doses. The injection goes just under the skin (abdomen, thigh or upper arm) and the site is rotated week to week. Most people build a quick weekly habit around it without much disruption.

The pen needs to be kept in the fridge between uses; many people store it in the fridge door alongside everyday items, which acts as a natural reminder. If you are working through the higher end of the dose schedule, our tirzepatide l page covers what to expect as you progress through those later stages. Storage temperature windows and the exact room-temperature allowance are specified in the leaflet inside the pack, follow those rather than relying on general summaries, since the guidance is precise and worth reading.

Tirzepatide is described as a Black Triangle medicine, meaning the MHRA collects additional safety data as clinical experience with it grows. That status does not mean it is experimental; it simply means post-market surveillance is active. If questions about the practical side of starting treatment are on your mind, our FAQ page covers many of the questions our prescribers hear most often. For a broader look at the weight-loss treatments we offer, our weight management overview gives useful context, and if you are considering the tirzepatide 30 supply option, this page explains exactly what that includes and how it works alongside this page on Mounjaro pricing, which explains what a private prescription typically includes. When you're ready to see whether tirzepatide could be suitable for you, check your eligibility with a free consultation, a GPhC-registered prescriber reviews every application the same day.